Hope in fight against inherited cancer
The first of a new class of drugs for cancer is showing promise in patients with inherited forms of the disease, researchers report.
Called olaparib, the new drug comes in pill form and targets cancer cells caused by the faulty BRCA1 or BRCA2 genes, which affects around 1,500 of the nearly 46,000 women diagnosed with breast cancer in the UK each year.
Women who inherit one of the abnormal genes have about a 60 per cent risk of developing breast cancer. They also sharply increase the risk of ovarian cancer, and of other cancers including cervical, uterine and bowel cancer. Although only a small group of patients are affected by the BRCA genes, the drugs have been shown in the laboratory to have potential benefits for a wider range of cancer types that share similar characteristics.
Results from two early stage studies published in The Lancet show that olaparib significantly reduced the size of tumours in over 40 per cent of women with advanced breast cancer given the highest dose, and over 33 per cent of those with advanced ovarian cancer. In both cases tumours were prevented from progressing for an average of six months.
Andrew Tutt, director of the Breakthrough Breast Cancer Research Unit at King's College London, who led the breast cancer study, said: "It was remarkable to see that olaparib benefited women with advanced breast and ovarian cancer who had already been treated with several different chemotherapy drugs. However, this drug is at an early stage of development, and further clinical trials will be required."
In a separate study, researchers have found that men who carry a faulty copy of the BRCA2 gene have a one in 15 chance of developing breast cancer by the time they are 70. Breast cancer is rare in men, with about 300 cases in Britain each year compared with more than 45,000 among women. But the lifetime risk among men with a faulty BRCA2 gene is 8.4 per cent by the age of 80, the researchers say in the Journal of Medical Genetics.
Life & Style blogs
Who is Teresa Fidalgo? Debunking the fake ghost story that's got Instagram spooked
Scottish salmon sales leap as Asia develops a taste
Grim second life of the 'breastaurant': The oft-loathed sector is booming in the States thanks to Hooters, Twin Peaks and Tilted Kilt
Health: When masturbation can be fatal: The practice of auto-erotic asphyxia is often concealed by a coroner's verdict. Monique Roffey looks at a lethal taboo
- 1 President of Argentina adopts Jewish godson to 'stop him turning into a werewolf'
- 2 ALS ice bucket challenge co-founder Corey Griffin drowns, aged 27
- 3 The 'Black Museum': After 150 years, public set to see exhibits from police’s grisly crime museum
- 4 AirAsia flight QZ8501 missing: Plane carrying 162 passengers from Indonesia to Singapore disappears over Java Sea
- 5 Naomi Wolf reacts to Isis 'conspiracy theories' critism after she questions whether beheading videos are real
£45000 - £55000 per annum: Recruitment Genius: This is an exciting opportunity...
£20000 per annum: Recruitment Genius: Panel Wireman required for small electro...
£25000 - £27000 per annum: Recruitment Genius: An SME based in East Cheshire, ...
£18000 - £22000 per annum: Recruitment Genius: Do you have previous experience...